Biomotion Sciences Ordinary Stock Performance
| SLXN Stock | 3.02 0.15 4.73% |
The firm shows a Beta (market volatility) of 2.71, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biomotion Sciences will likely underperform. At this point, Biomotion Sciences has a negative expected return of -1.07%. Please make sure to confirm Biomotion Sciences' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Biomotion Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Biomotion Sciences Ordinary has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (4.64) | Five Day Return 7.09 | Year To Date Return (89.88) | Ten Year Return (98.85) | All Time Return (98.85) |
Last Split Factor 1:15 | Last Split Date 2025-07-29 |
1 | Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7 percent Inhibition and First ... | 09/30/2025 |
2 | Insider Trading | 11/13/2025 |
3 | Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 23 Clinical Trial in Pancreati... | 11/25/2025 |
4 | Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 23 Clinical Trial in Pancreatic Cancer | 12/02/2025 |
| Begin Period Cash Flow | 4.6 M | |
| Total Cashflows From Investing Activities | -22 K |
Biomotion | Build AI portfolio with Biomotion Stock |
Biomotion Sciences Relative Risk vs. Return Landscape
If you would invest 710.00 in Biomotion Sciences Ordinary on September 8, 2025 and sell it today you would lose (408.00) from holding Biomotion Sciences Ordinary or give up 57.46% of portfolio value over 90 days. Biomotion Sciences Ordinary is currently does not generate positive expected returns and assumes 6.8061% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than Biomotion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biomotion Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biomotion Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biomotion Sciences Ordinary, and traders can use it to determine the average amount a Biomotion Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1567
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SLXN |
Estimated Market Risk
| 6.81 actual daily | 61 61% of assets are less volatile |
Expected Return
| -1.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biomotion Sciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biomotion Sciences by adding Biomotion Sciences to a well-diversified portfolio.
Biomotion Sciences Fundamentals Growth
Biomotion Stock prices reflect investors' perceptions of the future prospects and financial health of Biomotion Sciences, and Biomotion Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biomotion Stock performance.
| Return On Equity | -7.71 | ||||
| Return On Asset | -0.78 | ||||
| Current Valuation | 2.22 M | ||||
| Shares Outstanding | 3.13 M | ||||
| Price To Book | 1.35 X | ||||
| EBITDA | (16.48 M) | ||||
| Net Income | (16.52 M) | ||||
| Total Debt | 4.49 M | ||||
| Book Value Per Share | 2.23 X | ||||
| Cash Flow From Operations | (8.4 M) | ||||
| Earnings Per Share | 349.09 X | ||||
| Market Capitalization | 9.44 M | ||||
| Total Asset | 2.86 M | ||||
| Retained Earnings | (43.25 M) | ||||
| Working Capital | (1.27 M) | ||||
About Biomotion Sciences Performance
By examining Biomotion Sciences' fundamental ratios, stakeholders can obtain critical insights into Biomotion Sciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biomotion Sciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 5.77 | 6.05 | |
| Return On Capital Employed | 19.05 | 20.00 | |
| Return On Assets | 5.77 | 6.05 | |
| Return On Equity | (4.14) | (3.93) |
Things to note about Biomotion Sciences performance evaluation
Checking the ongoing alerts about Biomotion Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biomotion Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biomotion Sciences generated a negative expected return over the last 90 days | |
| Biomotion Sciences has high historical volatility and very poor performance | |
| Biomotion Sciences has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomotion Sciences generates negative cash flow from operations | |
| Biomotion Sciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 23 Clinical Trial in Pancreatic Cancer |
- Analyzing Biomotion Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biomotion Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Biomotion Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biomotion Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biomotion Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biomotion Sciences' stock. These opinions can provide insight into Biomotion Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Biomotion Sciences Ordinary. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in median. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomotion Sciences. If investors know Biomotion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomotion Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Biomotion Sciences is measured differently than its book value, which is the value of Biomotion that is recorded on the company's balance sheet. Investors also form their own opinion of Biomotion Sciences' value that differs from its market value or its book value, called intrinsic value, which is Biomotion Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomotion Sciences' market value can be influenced by many factors that don't directly affect Biomotion Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomotion Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomotion Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomotion Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.